title: [Psychiatry].
abstract: In 2008 there is no major breakthrough in the field of psychopharmacology. Paliperidone, (Invega), or 9-hydroxyrisperidone, the main hydroxylated metabolite of risperidone, is now available in Switzerland. It has the same pharmacodynamic profile and a different pharmacokinetic profile, linked to an extended release preparation. Bupropion, an antidepressant with noradrenergic and dopaminergic activity, is now accepted on the Swiss market for the treatment of depression under the name of Wellbutrin. Until now, its indication was limited to tobacco withdrawal (under the name of Zyban). The article also includes new data issued from the STAR*D study (concerning the efficacy of cognitive behavioural therapy) and a few remarks about the recent debate in the media about the efficacy of antidepressants.
authors.affiliation: Clinique La Métairie, Nyon. ngervasoni@lametairie.ch
authors.forename: Nicola
authors.initials: N
authors.lastname: Gervasoni
authors.forename: Christian
authors.initials: C
authors.lastname: Bryois
authors.forename: Rémy
authors.initials: R
authors.lastname: Barbe
authors.forename: Gilles
authors.initials: G
authors.lastname: Bertschy
mesh_terms: D000928:Antidepressive Agents / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000627:therapeutic use; D006801:Humans; D007555:Isoxazoles / Q000627:therapeutic use; D001523:Mental Disorders / Q000628:therapy*; D000068882:Paliperidone Palmitate; D011613:Psychotherapy; D011743:Pyrimidines / Q000627:therapeutic use
chemical_list: D000928:Antidepressive Agents; D014150:Antipsychotic Agents; D007555:Isoxazoles; D011743:Pyrimidines; D000068882:Paliperidone Palmitate